Improving T cell therapy for melanoma by overcoming resistance mechanisms
Official title: Leveraging cancer-evolved resistance mechanisms to enhance EZH2 activity in adoptive T cells
Funded at Univ of Arkansas for Med Scis · NIH-10947841 · Data updated 2026-11-12
This study is looking at ways to make CAR T cell therapy work better for people with advanced melanoma who haven't responded to other treatments, by figuring out how to help the T cells fight the cancer more effectively in tough conditions.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of Arkansas for Med Scis NIH-funded |
| Lab location | 1 site (Little Rock, United States) |
| Project start | June 1, 2024 |
| Project end | May 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $393,401 |
| NIH project number | 1R21CA292278-01 |
| Project ID | NIH-10947841 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with metastatic melanoma who have not responded to immune checkpoint blockade therapies.
✕Less likely to help
Patients with early-stage melanoma or those who have not yet undergone any form of immunotherapy may not benefit from this research.
What this research studies
This research focuses on enhancing the effectiveness of adoptive T cell therapy, particularly CAR T cells, for patients with metastatic melanoma who have developed resistance to current treatments. The approach involves understanding how the tumor microenvironment affects T cell function and finding ways to engineer T cells that can better survive and function in these challenging conditions. By targeting specific mechanisms that lead to T cell exhaustion, the research aims to improve the overall success of T cell therapies when combined with other treatments. Patients may benefit from more effective therapies that can overcome the limitations of existing options.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for melanoma patients who currently have limited options due to resistance to existing therapies.
How similar studies have gone: Previous research has shown promise in enhancing T cell therapies for cancer, indicating that this approach could lead to significant advancements in treatment.
Where this research is happening
-
Univ of Arkansas for Med Scis
Little Rock, United States Active
Researchers
- Principal investigator: Tackett, Alan — Univ of Arkansas for Med Scis
- Study coordinator: Tackett, Alan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.